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Abstract
Background: Restriction of fetal growth and compromise of fetal wellbeing remain significant
causes of perinatal death and childhood disability. At present, there is a lack of scientific consensus
about the best strategies for predicting these conditions before birth. Therefore, there is
uncertainty about the best management of pregnant women who might have a growth restricted
baby. This is likely to be due to a dearth of clear collated information from individual research
studies drawn from different sources on this subject.
Methods/Design:  A series of systematic reviews and meta-analyses will be undertaken to
determine, among pregnant women, the accuracy of various tests to predict and/or diagnose fetal
growth restriction and compromise of fetal wellbeing. We will search Medline, Embase, Cochrane
Library, MEDION, citation lists of review articles and eligible primary articles and will contact
experts in the field. Independent reviewers will select studies, extract data and assess study quality
according to established criteria. Language restrictions will not be applied. Data synthesis will
involve meta-analysis (where appropriate), exploration of heterogeneity and publication bias.
Discussion: The project will collate and synthesise the available evidence regarding the value of
the tests for predicting restriction of fetal growth and compromise of fetal wellbeing. The
systematic overviews will assess the quality of the available evidence, estimate the magnitude of
potential benefits, identify those tests with good predictive value and help formulate practice
recommendations.
Background
Restriction of fetal growth and compromise of its wellbe-
ing remain significant causes of perinatal death and child-
hood disability [1-3]. These babies on reaching adulthood
are at greater risk of developing cardiovascular disease,
hypertension, and non-insulin dependant diabetes [4,5].
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Reliable antenatal identification of the growth-restricted
fetus is crucial to judicious allocation of monitoring
resources and use of preventative treatment [6] with the
prospect of improving perinatal outcome. The variation in
the design of research on accuracy of tests for identifica-
tion of growth restriction and compromise of wellbeing,
the scatter of this research across many databases and lan-
guages, and the dearth of clear collated up-to-date sum-
maries of this literature contribute to the uncertainty
about the best diagnostic and monitoring strategies [7]. A
comprehensive systematic review of the literature on all
available tests can improve our ability to identify those
pregnancies at greatest risk of developing clinically rele-
vant intrapartum and neonatal consequences of impaired
fetal growth.
Screening and diagnosis of fetal growth restriction (FGR)
and prediction and monitoring for compromise of fetal
wellbeing in a clinical setting includes a combination of
patients' characteristics, symptoms, physical signs and
tests, which form the basis of clinical care. For instance,
methods employed to screen for and detect FGR might
include obtaining previous history of small babies,
recording symphyseal fundal height on a customised
growth chart and estimating fetal weight with ultrasound
[7]. Similarly, current history of fetal movements, abdom-
inal palpation to assess liquor volume, ultrasound amni-
otic fluid index, Doppler flow velocimetry and
cardiotocography might be used to assess fetal wellbeing
[7]. These and other tests outlined in Table 1 will be the
focus of our project to systematically review existing
research on their accuracy.
The term FGR (related term IUGR or intrauterine growth
retardation) and SGA (small for gestational age) are often
used interchangeably, but some times erroneously. Appre-
ciation of the difference between smallness of fetus as a
consequence of intra-uterine constraint as opposed to that
resulting from normal smallness is central to understand-
ing the meaning of FGR and the accuracy of tests to predict
FGR. SGA refers to any fetus that falls below a defined size
(e.g. below a particular centile below the population aver-
age by a given gestational age). It represents a heterogene-
ous group comprising of fetuses that have failed to achieve
their growth potential (true FGR) as well as fetuses that are
constitutionally small due to an inherent low growth
potential. Only about half of SGA fetuses (birth weight
below 10th centile for gestational age) have FGR. It is FGR
that is likely to be associated with childhood disability;
normal constitutional smallness is expected to be of no
clinical consequence. Hence a good fetal growth test will
be expected to accurately identify fetuses that have true
FGR, distinguishing FGR from SGA alone.
A distinction has earlier been made between tests that
measure fetal size or growth (e.g. biometric tests) and
those that assess fetal wellbeing (e.g. biophysical tests)
[7]. Tests of wellbeing are aimed at predicting fetal acidae-
mia, which is perceived, at least in the model of chronic
placental failure, to lead ultimately to organ damage and
death. Data from fetal blood sampling studies confirm
there is a correlation between fetal pH and neurodevelop-
mental outcome in small fetuses. This implies that the
accuracy of tests for FGR need to be assessed separately to
those used for assessment of fetal wellbeing, but existing
reviews often do not make this distinction.
The reference criteria for confirmation of growth restric-
tion and compromise of wellbeing are different and our
project will deal with this issue in a methodologically
sound manner. Many tests have been purported to be pre-
dict stillbirth, birth hypoxia and neonatal complications
[2]. To carefully and strictly define reference standards for
our project, we will undertake a systematic review of prog-
nostic studies relating neonatal features of FGR and well-
being to medium- and long-term outcome, thereby
establishing a hierarchy of reference standards. This
review will examine how well the available assessments at
birth assess the risk of impaired neurodevelopment, [3]
educational disadvantage [8] and illnesses (e.g. diabetes
mellitus, hypertension) in adult life [9]. We will also use
appropriate statistical methods suitable for meta-analysis
of studies with various reference standards [10].
Timely prediction of growth restriction and compromise
of fetal wellbeing is of essence in antenatal care. Without
accurate prediction, clinicians are handicapped. Wrong or
delayed prediction puts baby at risk of an adverse out-
come whereas correct prediction provides an opportunity
to optimise care. If high-risk groups are accurately and
efficiently identified, they could benefit from monitoring
of wellbeing and appropriate interventions such as steroid
administration and timely delivery. However, decision-
making is hampered due to lack of precise information on
estimates of risk, a situation that can be ameliorated with
a comprehensive systematic review of the literature.
Table 1: A sample of tests for prediction/diagnosis of fetal growth restriction and/or compromise of fetal wellbeing.
History Clinical risk scoring, abdominal palpation, symphyseal fundal height measurement, fetal movement counting.
Ultrasound Biometry, Doppler, amniotic fluid volume, placental grade, biophysical profile.
Biochemical Haematological e.g. oestriol, human chorionic gonadotrophin, alpha feto protein, pregnancy associated plasma protein (PAPP-
A), inhibin A.
Other tests Customised growth charts, cardiotocography, fetal electrocardiogram.BMC Pregnancy and Childbirth 2007, 7:3 http://www.biomedcentral.com/1471-2393/7/3
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Research in prevention of complications of growth restric-
tion itself will benefit form identification of high-risk
groups with accurate tests as these may be enrolled in clin-
ical trials with an improved likelihood of providing
robust evidence of effectiveness.
Methods/Design
Objectives
To generate a set of the most accurate tests for predicting
restriction of fetal growth and compromise of its wellbe-
ing, systematic reviews (meta-analyses) of test accuracy
studies will be conducted with the following objective:
To obtain summary estimates of accuracy of available
antenatal tests for predicting restriction of fetal growth
and compromise of fetal wellbeing.
Search Strategy
Literature will be identified using:
• General bibliographic databases including MEDLINE
(PubMED) and EMBASE (Ovid)
• Specialist electronic databases: The Cochrane Library
(DARE, CCTR), MEDION
• Contact with individual experts and those with an inter-
est in this filed to uncover grey literature
• Contact with manufacturers of tests
• Hand-searching of selected specialist journals
• Checking of reference lists of relevant review articles and
papers that will be eligible for inclusion
Two searches will be performed, the first looking at pre-
diction and diagnosis of FGR and the second at compro-
mise of fetal wellbeing. The comprehensive search
strategies will aim to find all primary studies reporting in
the accuracy of any test (or test combinations) used to pre-
dict or diagnose fetal growth restriction and/or compro-
mise of fetal wellbeing. The search for FGR may be viewed
as additional file 1: Search strategy for tests to predict/
diagnose fetal growth restriction. (other searches are avail-
able form the authors on request). This will be achieved
by combining search terms relating to FGR/compromise
of fetal wellbeing with methodological filters for identifi-
cation of aetiologic and diagnostic test studies (table 1)
[11-13]. All databases will be searched from inception and
updated at six monthly intervals. No language restrictions
will be applied. A comprehensive database of the litera-
ture will be constructed (Reference Manager 11.0).
Inclusion criteria
Studies will be selected for inclusion in the reviews using
the selection criteria based on population, index test, ref-
erence standard and study design of interest.
Population: Pregnant women any health care setting, any
level of risk.
Diagnostic tests: Tests will be prioritised on the basis of
clinical relevance after consultation with experts in the
field. (see table 1)
Reference standard: Any measurement of birth weight or
nutritional status of newborn performed postnatally.
Study design: Observational test accuracy studies (cohorts,
case-control prospective) allowing generation of 2 × 2
tables of accuracy. Case series <10 cases and case-control
studies defined by reference standard outcome (birth
weight measurement) will be excluded, these study
designs have been shown to be associated with bias [14].
Sub-groups: Severe FGR will be defined as that leading to
premature delivery (<37 completed weeks), wherever pos-
sible test accuracy for prediction/diagnosis of severe FGR
will be assessed.
Study selection process
Studies will be selected for inclusion in the review in a
two-stage process using the selection criteria detailed
above. Firstly, the titles and abstracts of the citations in the
Reference manager database will be assessed by one
reviewer. All papers felt to be relevant will be obtained in
full text version. Two reviewers will then independently
select the studies, which meet predefined and explicit cri-
teria regarding population, tests, reference standards and
study design (defined prior to commencement of the
review and individualised for each review). Disagree-
ments will be resolved by consensus or arbitration of a
third reviewer.
Data extraction
For each review a data extraction form will be designed,
variation between reviews will mainly be in the informa-
tion extracted for the performance of the index test. Data
will be extracted on: identification of study (first author,
year of publication, country of investigation, language of
paper); population (healthcare setting, number of partici-
pating centres, level of risk assigned by author and clinical
data on risk factors, inclusion period); study design
(design, data collection, enrolment, completeness of veri-
fication); index test (gestation, method of performance of
test, intra and interobserver variation, cut-off level); refer-
ence standard (incidence, reference standard used, cut-off
level, total number of women analysed for results); resultsBMC Pregnancy and Childbirth 2007, 7:3 http://www.biomedcentral.com/1471-2393/7/3
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(necessary data for construction of 2 × 2 table, all results
will be collected for any index test reported at any cut-off
level, any measurement of statistical accuracy reported).
The extraction of a study's findings will be conducted in
duplicate using the data extraction form. This will help
avoid errors in data extraction, disagreements between
reviewers will again be resolved by consensus or arbitra-
tion of a third reviewer where necessary. Where multiple
publications are identified, the most recent and/or com-
plete study will be included only. Data will be entered
onto an Excel spreadsheet, after checking of the duplicate
extraction forms has resolved any errors.
Quality assessment
All included manuscripts will be assessed by at least one
reviewer for study and reporting quality. Methodological
quality is defined as the confidence that the study design,
conduct and analysis have minimized biases in addressing
the research question, thereby focusing on the internal
validity (i.e. the degree to which the results of an observa-
tion are correct for the patients being studied), this will be
assessed using the QUADAS tool [15,16]. Elements of
study design which are likely to have a direct relationship
to bias in a test accuracy study will be assessed using the
STARD checklist [17].
In the assessment of study quality for the population, con-
secutive or random recruitment of pregnant women will
be considered ideal. Prospective recruitment is considered
to introduce less bias than retrospective recruitment. The
description of the population will be considered ideal if
there is sufficient information about the pregnant women
given to assign a level of obstetric risk, ideally this risk
level will be stated by the authors in the study's methods.
The incidence of FGR will be calculated for each study and
used as a check for the author's quantification of the risk
category of the population.
Assessing the quality of performance and reporting of the
index standard will be individualised for each test ena-
bling the assessment to look at individual aspects of each
test that might introduce bias. For the reference standard,
any representation of birth weight or nutritional status of
the newborn will be considered acceptable. Information
will be collected on method of determination of reference
standard, execution and blinding.
Ideal study design will be trials or cohort studies, case-
control studies will not be included wherever possible,
when the number of studies will allowed this, they will
however be excluded from meta-analysis as recent papers
have shown that this type of study design can affect accu-
racy [14].
Verification bias will be assessed using a flow chart for
each study which will document the number of eligible
women for the study, the number of women subjected to
the index test, the number of women receiving the refer-
ence standard and the number of exclusions, withdrawals
and uninterpretable results. Ideal verification will be
when all women can be accounted for and the number of
eligible women progressing to the reference standard is
>90%.
The assessment of quality will be represented by a bar
chart. No attempt will be made to apply a quality score as
this has been shown to have little validity [18] and quality
will not be used as an aspect for inclusion/exclusion of
studies from meta-analysis. Wherever possible for each
review, an individual assessment will be made of the most
important quality items for that test and studies defined as
high or low quality. This definition will be used in the
sub-group analysis wherever possible.
Methods of statistical analysis
From the 2 × 2 tables, the true positive rate (sensitivity),
false positive rate (1-specificity) and likelihood ratios
(LRs) will be calculated for each study along with their
95% confidence intervals (CIs). Where 2 × 2 tables con-
tained zero cells, 0.5 will be added to each cell to enable
calculations [19]. In each review, results will be visualised
using Forrest plots and ROC plots, extreme values, out-
liers and threshold phenomena will be explored.
Where appropriate meta-analysis will be used. Pooled
summary estimates will be produced in the form of the
summary likelihood ratio as this is the measure which is
most applicable clinically, in keeping with recommenda-
tions from Evidence-based Medicine Groups [20,21]. The
likelihood ratios allow estimation of the probability of
FGR or neonatal compromise with a specific test result. To
generate the practical application of these LRs the post test
probability of having the disease will be generated using
Bayes' theorem and the following formula: post test prob-
ability = likelihood ratio × pre-test probability/[1-pre-test
probability × (1-likelihood ratio)]. Estimates of pre-test
probability will be made using reports from previous
studies and taking into account the risk rates for the pop-
ulation in question. The range of uncertainty will be cal-
culated using the 95% confidence intervals of the
likelihood ratios for each test. Either a fixed or random
effects model will be used where appropriate following
widely published guidelines for their use.
Heterogeneity of results between studies will be assessed
graphically by looking at the distribution of sensitivities
and specificities in the receiver operating characteristic
(ROC) space and LRs as measurement of accuracy size
using a Forrest plot. The loglikelihood and X2 test will beBMC Pregnancy and Childbirth 2007, 7:3 http://www.biomedcentral.com/1471-2393/7/3
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used to assess for heterogeneity statistically. Where heter-
ogeneity is not present (X2 > 0.10) the fixed effect pooling
method will be used and where possible we will consider
the use of the bivariate meta-regression model [22,23].
The model assumes a bivariate normal distribution for the
logit-transformed sensitivity and specificity across studies,
using a random effects approach for both sensitivity and
specificity, allowing for heterogeneity beyond chance due
to clinical or methodological differences between studies.
In addition, the model acknowledges the difference in
precision by which sensitivity and specificity have been
measured in each study. The model produces the follow-
ing results: a random effect estimate of the mean sensitiv-
ity and specificity with corresponding 95% CIs, the
amount of between-study variation for sensitivity and spe-
cificity separately, and the strength and shape of the corre-
lation between sensitivity and specificity. When
heterogeneity is present (X2 < 0.10) this will be explored
using meta-regression analyses. This will be performed
using factors considered to be important beforehand,
including:
• Variations in population – high and low risk defined by
prevalence of FGR within the population.
• Variations in index test – e.g. type of test parameter, cut-
off used
• Variations in reference standard – test used, threshold
used
• Study quality
• Study design – cohort studies only.
Analysis for assessing the risk of publication bias will be
carried out by producing funnel plots [24] of accuracy
estimates against corresponding variances. When no pub-
lication bias is present the plots will be shaped like a fun-
nel because studies of smaller size are expected to have
increased variation in the estimates of accuracy. The big-
ger the study variance, the lower the weighting of the
study and the less information it provides. This means
that in addition to small sample size of included primary
studies, those studies reporting very high accuracy will
also have a relatively big variance and thus be weighted
less. There is however debate about methods for this issue
in diagnostic reviews [25].
Data synthesises were performed using Meta-DiSc version
1.4[26], SATA version 9.0 and SAS version 8.2.
Data description
For each test, information on individual studies was sum-
marised as follows:
• Table with methodological and reporting characteris-
tics of included studies.
The table states the number of women tested in each
study, the incidence of fetal growth restriction (based on
the number of analysed cases divided by the total number
of women at baseline (cohort studies and nested case-con-
trol studies)) and maternal age (given as mean (± SD) for
the whole group unless otherwise stated).
•  Summary of quality and reporting items of the
included studies.
Results were presented as 100% stacked bars, where fig-
ures in the stacks represent the number of studies. The
item 'study design' is stated in the table with quality and
reporting characteristics.
• Forest plots of sensitivities (%) and specificities (%)
and 95% CIs.
Studies are ranked according to decreasing specificity
(within subgroups). Numbers of women analysed are tp/
(tp+fn) for sensitivity and tn/(fp+tn) for specificity.
• ROC plot.
Estimates of predictive accuracy from individual studies
are shown (separate for subgroups if appropriate) and
where possible a summary ROC curve was drawn. In the
summary ROC plots the vertical axis shows sensitivity,
while the horizontal axis shows one-minus-specificity.
• Table with subgroup analyses. (If applicable.)
Significance level p < 0.10.
Discussion
The methodology of diagnostic systematic reviews is rap-
idly developing with the recent development of guidelines
on conducting primary studies [27] and their reporting
[17] and validation of quality assessment tools [16]. This
has lead to studies investigating the affect of study design
and conduct on diagnostic accuracy [14,28]. The bivariate
method is a statistical method designed specifically for
diagnostic data and its use will allow us to estimate the
degree of correlation between sensitivity and specificity
and thus provide information about heterogeneity and
the possibility if an implicit threshold [22,29].
This project will utilise all the recent developments in
methodology of systematic reviews of diagnostic tests as
well as developments in statistical analysis. The results of
the reviews will help produce a set of accurate tests to pre-
dict/diagnose fetal growth restriction and compromise ofBMC Pregnancy and Childbirth 2007, 7:3 http://www.biomedcentral.com/1471-2393/7/3
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its wellbeing that can be incorporated into guidelines for
clinical practice.
One of the anticipated problems with this project is the
lack of knowledge surrounding measurements of weight
at birth and nutritional measures and there relation to
neonatal morbidity and mortality and future childhood
disability [30][31][32][33][34]. We will thus also aim to
undertake a systematic review of prognostic studies relat-
ing neonatal features to outcome (e.g. childhood disabil-
ity, neurodevelopmental outcome) thereby establishing a
hierarchy of reference standards. This will not only help us
with the interpretation of the results from our diagnostic
accuracy reviews but also help guide future primary
research. Results will be available through 2007–08.
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